LEXEO plans to initiate a Phase 1 clinical trial of LX2006 in patients with cardiomyopathy associated with FA and expects initial data from the Phase 1 trial of LX1001 in APOE4 associated Alzheimer’s disease in 2021.
Thursday, April 29, 2021
LEXEO Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting
NEW YORK, April 28, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced upcoming presentations regarding its investigational gene therapy programs at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, taking place virtually from May 11-14, 2021.
he AAVrh.10 vector is currently being evaluated by LEXEO in pre-clinical studies for the treatment of cardiomyopathy associated with Friedreich’s ataxia (FA). Cardiomyopathy is the most common cause of mortality in patients with FA; it is the cause of death in nearly 70% of the patient population.
